Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study

Real-world data showed that ustekinumab is an effective treatment for Crohn’s disease for up to 52 weeks. Yet, long-term effectiveness and safety outcomes beyond 52 weeks are limited. This study aimed to evaluate the corticosteroid-free clinical remission for up to 104 weeks. Secondary aims were foc...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Pepijn W.A., van Caem, Mark, West, Rachel L., Russel, Maurice G.V.M, Jansen, Jeroen M., Römkens, Tessa E.H., Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2022
Materias:
Original Articles: Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935642/
https://www.ncbi.nlm.nih.gov/pubmed/36708296
http://dx.doi.org/10.1097/MEG.0000000000002506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935642/
https://www.ncbi.nlm.nih.gov/pubmed/36708296
http://dx.doi.org/10.1097/MEG.0000000000002506

Ejemplares similares